Symphony Limited has informed the Exchange regarding a press release dated August 01, 2025, titled "Jun 25 Qtr. Result".
SYMPHONY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Symphony Limited reported a weak June 2025 quarter, with standalone revenue declining 39% year-on-year to ₹229 crore and EBITDA falling 71% to ₹24 crore, attributed to seasonal headwinds, early monsoon onset, and a high base from the June 2024 quarter. Despite the YoY drop, the quarter was the company's second-highest June quarter standalone revenue on record. Consolidated revenue fell 36% to ₹251 crore, with consolidated PAT at ₹42 crore (down 52%). The Board approved an interim dividend of ₹1 per share (face value ₹2) for FY26. Subsidiaries showed mixed performance: GSK China continued strong growth and repaid ₹27.9 crore of inter-company loans (reducing outstanding to ₹26.1 crore from a peak of ₹59.8 crore), IMPCO Mexico remained subdued due to a milder summer, and Symphony AU Australia posted its second consecutive quarter of YoY growth. GSK China also transferred technology and 9 IPRs to IMPCO Mexico in a ~₹44 crore deal to enable IMPCO's future divestment.
The sharp YoY declines in revenue and margins may pressure the stock in the short term, though the seasonal nature of the business and the interim dividend offer some cushion. Longer-term, GSK China's debt reduction trajectory and growth momentum, along with strategic moves to scale the 'Air Force' range and counter-seasonal categories, are positive signals for shareholders.